Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.59 |
| ▸ | HTR1A | P08908 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 5/20 | 0.52 |
| ▸ | HTR7 | P34969 | 4/20 | 0.52 |
| ▸ | HTR6 | P50406 | 4/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.52 |
| ▸ | DRD3 | P35462 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252277 | 0.97 | DRD2 (0.67) | DRD2TRPV1HTR1AHTR2AHTR7 | |
| SCHEMBL252200 | 0.96 | DRD2 (0.71) | DRD2TRPV1HTR1AHTR2AHTR7 | |
| SCHEMBL254909 | 0.94 | DRD2 (0.72) | DRD2TRPV1HTR1AHTR2AHTR7 | |
| SCHEMBL252062 | 0.84 | DRD2 (0.93) | DRD2HTR1AHTR2ADRD3KCNH2 | |
| SCHEMBL252276 | 0.84 | DRD2 (0.93) | DRD2HTR1AHTR2ADRD3KCNH2 | |
| SCHEMBL3402211 | 0.83 | DRD2 (0.73) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL253470 | 0.81 | DRD2 (0.51) | DRD2TRPV1HTR1AHTR2A | |
| SCHEMBL14984460 | 0.80 | DRD2 (0.70) | DRD2TRPV1HTR1AHTR2ADRD3 | |
| SCHEMBL253514 | 0.80 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL253399 | 0.80 | DRD2 (0.71) | DRD2HTR1AHTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | claimed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | claimed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | DRD2 1/4885TRPV1 280/4885HTR1A 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.